Patents by Inventor Eddi Meier
Eddi Meier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190076506Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: May 22, 2018Publication date: March 14, 2019Inventors: Ditte RIBER, Eddi MEIER, Jens Rosengren DAUGAARD, Marie SKOVGAARD, Jakob Lind TOLBORG, Gita KAMPEN, Camilla Ærteberg BÆK
-
Patent number: 10004786Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: GrantFiled: September 2, 2015Date of Patent: June 26, 2018Assignee: Zealand Pharma A/SInventors: Ditte Riber, Eddi Meier, Jens Rosengren Daugaard, Marie Skovgaard, Jakob Lind Tolborg, Gita Kampen, Camilla Ærteberg Bæk
-
Publication number: 20160304576Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: June 27, 2016Publication date: October 20, 2016Inventors: Eddi MEIER, Ditte RIBER, Jens Rosengren DAUGAARD, Marie SKOVGAARD
-
Patent number: 9403894Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the glucagon-like peptide-1 (GLP-1) receptor as compared to human glucagon.Type: GrantFiled: June 23, 2011Date of Patent: August 2, 2016Assignee: Zealand Pharma A/SInventors: Eddi Meier, Ditte Riber, Jens Rosengren Daugaard, Marie Skovgaard
-
Publication number: 20160120951Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: September 2, 2015Publication date: May 5, 2016Inventors: Ditte RIBER, Eddi MEIER, Jens Rosengren DAUGAARD, Marie SKOVGAARD, Jakob Lind TOLBORG, Gita KAMPEN, Camilla Ærteberg BÆk
-
Publication number: 20150376257Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain and for treating diabetes and associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptide compounds effective in such methods. The compounds may mediate their effect by having, for example, increased selectivity for the GLP-1 receptor compared to human glucagon.Type: ApplicationFiled: September 14, 2015Publication date: December 31, 2015Inventors: Ditte RIBER, Eddi MEIER
-
Patent number: 9169310Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain and for treating diabetes and associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptide compounds effective in such methods. The compounds may mediate their effect by having, for example, increased selectivity for the GLP-1 receptor compared to human glucagon.Type: GrantFiled: June 24, 2011Date of Patent: October 27, 2015Assignee: Zealand Pharma A/SInventors: Ditte Riber, Eddi Meier
-
Patent number: 9156901Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: GrantFiled: June 24, 2010Date of Patent: October 13, 2015Inventors: Ditte Riber, Eddi Meier, Jens Rosengren Daugaard, Marie Skovgaard, Jakob Lind Tolborg, Gita Kampen, Camilla Ærteberg Bæk
-
Publication number: 20150080295Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: March 3, 2014Publication date: March 19, 2015Applicant: Zealand Pharma A/SInventors: Eddi MEIER, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard
-
Publication number: 20140127175Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: January 7, 2014Publication date: May 8, 2014Inventors: Eddi MEIER, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard
-
Publication number: 20140127174Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: January 7, 2014Publication date: May 8, 2014Inventors: Eddi MEIER, Ditte Riber, Marie Skovgaard, Bjarne D. Larsen, Jens R. Daugaard, Trine S. R. Neerup
-
Patent number: 8685919Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: GrantFiled: December 15, 2008Date of Patent: April 1, 2014Assignee: Zealand Pharma A/SInventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard
-
Patent number: 8680049Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: GrantFiled: December 15, 2008Date of Patent: March 25, 2014Assignee: Zealand Pharma A/SInventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard, Trine Skovlund Ryge Neerup
-
Patent number: 8642540Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: GrantFiled: December 15, 2008Date of Patent: February 4, 2014Assignee: Zealand Pharma A/SInventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard
-
Patent number: 8642541Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: GrantFiled: December 15, 2008Date of Patent: February 4, 2014Assignee: Zealand Pharma A/SInventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard, Trine Skovlund Ryge Neerup
-
Publication number: 20130157935Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: June 23, 2011Publication date: June 20, 2013Applicant: Zealand Pharma A/SInventors: Eddi Meier, Ditte Riber, Jens Rosengren Daugaard, Marie Skovgaard
-
Publication number: 20130157929Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain and for treating diabetes and associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptide compounds effective in such methods. The compounds may mediate their effect by having, for example, increased selectivity for the GLP-1 receptor compared to human glucagon.Type: ApplicationFiled: June 24, 2011Publication date: June 20, 2013Applicant: ZEALAND PHARMA A/SInventors: Ditte Riber, Eddi Meier
-
Publication number: 20130157953Abstract: The invention relates to the treatment of cardiac dysfunction. In particular, certain compounds, believed to be glucagon-GLP-1 dual agonist compounds, exert a positive inotropic effect while preserving the energy balance of the heart, and so may be superior to known inotropic agents such as dobutamine, norepinephrine and glucagon.Type: ApplicationFiled: January 20, 2011Publication date: June 20, 2013Applicant: Zealand Pharma A/SInventors: Jørgen Søberg Petersen, Anne Louise Kjoelbye, Marie Skovgaard, Henrik Duelund Pedersen, Lene Axelsen, Ditte Riber, Eddi Meier, Rie Schultz Hansen, Keld Fosgerau, Bjarne Due Larsen
-
Publication number: 20120178670Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: June 24, 2010Publication date: July 12, 2012Applicant: Zealand Pharma A/SInventors: Ditte Riber, Eddi Meier, Jens Rosengren Daugaard, Marie Skovgaard, Jakob Lind Tolborg, Gita Kampen, Camilla Ærteberg Bæk
-
Publication number: 20110293587Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: December 15, 2008Publication date: December 1, 2011Applicant: Zealand Pharma A/SInventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard, Trine Skovlund Ryge Neerup